Wall Street stocks were trading modestly lower Monday as the main indexes pulled back amid mixed earnings.
The Dow Jones Industrial Average DJIA, -0.06% was hovering around break-even levels at 20.061. The blue-chip index was switching between small gains and losses, as a gain in United Technologies Corp. UTX, +0.96% was offset by a loss in shares of Intel Corp. INTC, -0.78%
The S&P 500 SPX, -0.19% eased 3 points, or 0.2%, to 2,293, with nearly all main sectors trading lower, with energy and real-estate sectors leading the losses.
The Nasdaq Composite COMP, -0.04% slipped 3 points, or less than 0.1%, to 5,663.
A Chinese psychiatrist who took 64 mental patients with him when he moved to a better-funded hospital has sparked debate about doctors’ professional freedoms as China tries to encourage private capital to enter its strained healthcare system.
A state-run hospital in the southern province of Guizhou notified local police last week when Yang Shaolei, its director of psychiatry, transferred all but one of his ward’s patients to a privately backed rival after submitting his resignation. Over the weekend, Guihang 300 Hospital vowed to sue Dr Yang, attacking his actions as “an organised violation of medical consent and medical professional guidelines . . . which tramples on industry rules for healthy competition”.
Amicus Therapeutics, Inc (NASDAQ:FOLD), with shares high 0.69% is now trading at $5.81. The Stock is active as 505,073.00 shares changed hands versus its average volume of 3.39M shares. For investors focus on the performance of the stocks so the FOLD showed weekly ahead performance of 7.5% which was maintained for the month at 0.43%.
Amicus Therapeutics (FOLD), a global biotechnology company at the forefront of therapies for rare and orphan diseases, recently declared that Chip Baird, Chief Financial Officer, will take part in a corporate overview and fireside chat at the Leerink Partners 6th Annual Global Healthcare Conference in New York, NY on Thursday, February 16, 2017 at 11 a.m. ET.
Amicus Therapeutics (FOLD) is a biotechnology company at the forefront of therapies for rare and orphan diseases. The Company has a robust pipeline of advanced therapies for a broad range of human genetic diseases.
Infinity Pharmaceuticals Inc (NASDAQ:INFI), with shares surged 9.57% is now trading at $2.52. The Stock is active as 664,754.00 shares changed hands versus its average volume of 1.26M shares. The stock is going forward its 52 week low with 200.00% and lagging behind from its 52 week high price with – 63.85%. INFI last month stock price volatility remained 10.97%.
Infinity Pharmaceuticals, Inc. (INFI) will be participating in the 2017 BIO CEO & Shareholder Conference in New York City on Monday, February 13, 2017. During the conference, Joseph Pearlberg, M.D., Ph.D., vice president, clinical development at Infinity will take part in a panel at 11:00 a.m. ET entitled, “CAR-T, TILs, and Bispecifics: Immuno-Oncology Challenges and Opportunities.”
In Addition To, Adelene Perkins, Infinity’s chair and chief executive officer will provide an overview of the company on Monday, February 13, at 3:00 p.m. ET.